Table 3 Characteristics of patients achieved pCR

Total

25 (0.346)

32 (2.894)

Age

  ≤ 50

14 (1.118)

1.253 (0.574–2.735)

0.872

19 (1.340)

1.283 (0.422–3.896)

0.660

N/A^a

N/A

  > 50

11 (0.894)

Reference

13 (0.746)

Reference

Menopausal status

 Pre

15 (1.235)

1.191 (0.462–3.069)

0.717

18 (0.827)

0.827 (0.278–2.459)

0.732

N/A

N/A

 Post

10 (0.810)

Reference

14 (1.210)

Reference

cT stage (pre-treatment)

 1

3 (1.364)

2.250 (0.308–16.411)

0.577

5 (N/A)

4.167 (0.731–23.759)

0.108

1.823 (0.280–11.849)

0.530

 2

17 (3.101)

4.125 (0.493–34.499)

22 (0.776)

 3

2 (0.403)

1.632 (0.328–8.112)

3 (2.273)

 4

3 (0.709)

Reference

2 (0.240)

Reference^b

Reference^b

HR

 Negative

12 (1.278)

1.243 (0.488–3.183)

0.649

21 (6.491)

6.873 (2.008–23.552)

0.002

5.097 (1.335–19.465)

0.017

 Positive

13 (0.782)

Reference

11 (0.154)

Reference

Reference

HER2

 IHC2 + /FISH + 

4 (1.122)

1.101 (0.305–3.967)

0.884

1 (0.153)

0.153 (0.016–1.475)

0.104

0.336 (0.032–3.530)

0.364

 IHC3 + 

21 (0.892)

Reference

31 (6.526)

Reference

Reference

Ki67

  < 20%

2 (0.683)

0.671 (0.129–3.477)

0.634

4 (0.952)

0.952 (0.192–4.732)

0.952

N/A

N/A

  ≥ 20%

23 (1.464)

Reference

28 (1.050)

Reference

Chemotherapy regimens before surgery

 AC-T

17 (1.181)

Reference

0.661

21 (1.018)

0.778 (0.217–2.793)

0.650

N/A

N/A

 TCb

7 (1.620)

1.511 (0.157–14.499)

9 (1.409)

2.1 (0.312–14.152)

 T

1 (0.475)

0.648 (0.219–1.919)

2 (0.444)

Reference